-
Lorcaserin,
marketed under the
brand name Belviq, was a weight-loss drug
developed by
Arena Pharmaceuticals. It
reduces appetite by
activating serotonin...
- derivatives, such as
Lorcaserin (Figure 6) have been
evaluated for
their potency and
selectivity for the 5-HT2C receptors.
Lorcaserin is a very
potent agonist...
-
Michele (May 8, 2013). "Schedules of
Controlled Substances:
Placement of
Lorcaserin Into
Schedule IV".
Federal Register. Drug
Enforcement Administration....
-
serotonin receptors in a
region of the
brain called the hypothalamus.
Lorcaserin (Belviq) was FDA
approved for
weight loss but was
withdrawn from the market...
- on the market,
Belviq (
lorcaserin), a weight-loss medication. The U.S. Food and Drug
Administration (FDA)
approved lorcaserin on June 27, 2012. The company...
- its
potential for
causing valvulopathies and
pulmonary hypertension)
Lorcaserin (withdrawn in the
United States by the FDA due to an
increased risk of...
-
production of BI-4752, a
invented 5-HT2C
agonist that is even
better than
lorcaserin. Womack, E. B.; Nelson, A. B. (1944). "Ethyl Diazoacetate".
Organic Syntheses...
- as fenfluramine, dexfenfluramine, chlorphentermine, sibutramine, and
lorcaserin, have been
approved and used as
appetite suppressants for
purposes of...
- is a
benzazepine derivative structurally related to the
anorectic drug
lorcaserin. It is
selective for 5-HT2A, with an EC50 of 0.4nM at 5-HT2A vs 3.9nM...
- "FDA
requests the
withdrawal of the weight-loss drug Belviq,
Belviq XR (
lorcaserin) from the market". FDA.
Retrieved 17
February 2020.
Central Drugs Standard...
